Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus
Journal Title: Endokrynologia, Diabetologia i Choroby Przemiany Materii Wieku Rozwojowego - Year 2005, Vol 11, Issue 3
Abstract
Background: Currently continuous subcutaneous insulin infusion (CSII) as a method of functional intensive insulin therapy is the most physiological way to administer insulin. In recent years treatment with insulin pumps has been used more frequently in the paediatric diabetes whereas application of this kind of therapy is relatively new in the youngest group of children below the age of 10 years. The aim of the study was to assess the efficiency of CSII by means of insulin pumps in prepubertal children with type 1 diabetes mellitus (T1DM). Materials and methods: Three groups of T1DM children on intensive insulin therapy were compared. Group 1 comprised 30 children with CSII in the mean age 6.7±2.2 SD years (CSII-1). In group 2 were 25 children treated with multiple injections (MI-1) in the mean age 7.0±1.5 SD years and in group 3-35 children in the mean age 13.9±2.1 SD years treated with CSII (group CSII-2). The age of children was comparable in group CSII-1 and MI-1. T1DM duration was the same for all groups. After 6, 12, 18 months the following parameters were analyzed,: HbA1c, daily insulin requirement (DIR) U/kg, number of severe hypoglycemic episodes and diabetic ketoacidosis (DKA). Results: After 18 months in CSII-1 HbA1c decreased insignificantly from 7.1% to 6.9% and DIR was significantly reduced from 0.86 U/kg/24 h to 0.7 U/kg/24 h (after 6 months) and to 0,75 U/kg/24 h (after 12 months) and 0.77 U/kg/24 h after 18 months. In the MI-1 group HbA1c increased significantly from 7.0% to 7.4% in the 6th month and to 7.3% in the 18th month. DIR increased significantly from 0.68 U/kg/24 h to 0.76 U/kg/24 h; 0,8 U/kg/24 h and 0.84 U/kg/24 h after 6, 12, and 18 months respectively. There were no significant differences in HbA1c and DIR values in CSII-2 group after 18 months of observation. Significant difference of DIR was found in: CSII-1 vs. MI-1 and CSII-2 (p
Authors and Affiliations
Mariola Minkina-Pędras, Przemysława Jarosz-Chobot, Ewa Małecka-Tendera, Grażyna Deja
Keywords
Related Articles
- EP ID EP83617
- DOI -
- Views 106
- Downloads 0
Ocena wydzielania hormonu wzrostu po zaśnięciu jako badanie przesiewowe w diagnostyce somatotropinowej niedoczynności przysadki
Wprowadzenie: Diagnostyka somatotropinowej niedoczynności przysadki stanowi dla klinicysty nadal złożony problem. Fakt ten jest spowodowany w głównej mierze niedoskonałością testów stymulacyjnych, oceniających sekrecję h...
Rodzinne przedwczesne dojrzewanie płciowe – wariant normy, czy patologia?
Opisy dotyczące rodzinnego przedwczesnego dojrzewania płciowego (FPP) po raz pierwszy pojawiły się w 1937 r. Są one nieliczne, a większość z nich dotyczy tylko jednej, najlepiej poznanej postaci rodzinnego przedwczesnego...
Genetic syndrome, most likely vascular type of Ehlers-Danlos syndrome, in a 14-years old boy with extrapyramindal symptoms dominating the early childhood and growth failure
Introduction: The Ehlers-Danlos Syndrome (EDS) is a heterogeneous group of rare genetic disorders with various clinical features, which result from faulty collagen structure or disturbances in collagen synthesis. The ca...
Prediction of the clinical remission using the C-peptide level in type 1 diabetes in children
The aim of the study was to identify individual, clinical and metabolic factors that predict the C-peptide levels and appearance of clinical partial remission during the first year of type 1 diabetes (T1D) in children....
Ocena wpływu terapii ludzkim hormonem wzrostu na narzad wzroku pacjentów z somatotropinowa niedoczynnościa przysadki i pacjentek z zespołem Turnera.